These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34652819)

  • 1. An anthropomorphic pelvis phantom for MR-guided prostate interventions.
    Bauer DF; Adlung A; Brumer I; Golla AK; Russ T; Oelschlegel E; Tollens F; Clausen S; Aumüller P; Schad LR; Nörenberg D; Zöllner FG
    Magn Reson Med; 2022 Mar; 87(3):1605-1612. PubMed ID: 34652819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technical Note: ADAM PETer - An anthropomorphic, deformable and multimodality pelvis phantom with positron emission tomography extension for radiotherapy.
    Gillmann C; Homolka N; Johnen W; Runz A; Echner G; Pfaffenberger A; Mann P; Schneider V; Hoffmann AL; Troost EGC; Koerber SA; Kotzerke J; Beuthien-Baumann B
    Med Phys; 2021 Apr; 48(4):1624-1632. PubMed ID: 33207020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 3: Targeted Biopsy.
    Venderink W; Bomers JG; Overduin CG; Padhani AR; de Lauw GR; Sedelaar MJ; Barentsz JO
    Eur Urol; 2020 Apr; 77(4):481-490. PubMed ID: 31791623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ADAM-pelvis phantom-an anthropomorphic, deformable and multimodal phantom for MRgRT.
    Niebuhr NI; Johnen W; Echner G; Runz A; Bach M; Stoll M; Giske K; Greilich S; Pfaffenberger A
    Phys Med Biol; 2019 Feb; 64(4):04NT05. PubMed ID: 30630152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging/transrectal ultrasonography fusion guided seed placement in a phantom: Accuracy between 2-seed versus 1-seed strategies.
    Li Q; Duan Y; Baikpour M; Pierce TT; McCarthy CJ; Thabet A; Chan ST; Samir AE
    Eur J Radiol; 2020 Aug; 129():109126. PubMed ID: 32544805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.
    Pokorny MR; de Rooij M; Duncan E; Schröder FH; Parkinson R; Barentsz JO; Thompson LC
    Eur Urol; 2014 Jul; 66(1):22-9. PubMed ID: 24666839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
    Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
    Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. End-to-end test for fractionated online adaptive MR-guided radiotherapy using a deformable anthropomorphic pelvis phantom.
    Elter A; Rippke C; Johnen W; Mann P; Hellwich E; Schwahofer A; Dorsch S; Buchele C; Klüter S; Karger CP
    Phys Med Biol; 2021 Dec; 66(24):. PubMed ID: 34845991
    [No Abstract]   [Full Text] [Related]  

  • 9. Development and evaluation of a novel MR-compatible pelvic end-to-end phantom.
    Cunningham JM; Barberi EA; Miller J; Kim JP; Glide-Hurst CK
    J Appl Clin Med Phys; 2019 Jan; 20(1):265-275. PubMed ID: 30411477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and evaluation of an anatomically correct multi-image modality compatible phantom for prostate cancer focal ablation.
    Lindner U; Lawrentschuk N; Weersink RA; Raz O; Hlasny E; Sussman MS; Davidson SR; Gertner MR; Trachtenberg J
    J Urol; 2010 Jul; 184(1):352-7. PubMed ID: 20488477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
    van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO
    Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An end-to-end test for MR-guided online adaptive radiotherapy.
    Hoffmans D; Niebuhr N; Bohoudi O; Pfaffenberger A; Palacios M
    Phys Med Biol; 2020 Jun; 65(12):125012. PubMed ID: 32294637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of a 2
    Bomers JGR; Bosboom DGH; Tigelaar GH; Sabisch J; Fütterer JJ; Yakar D
    Eur Radiol; 2017 Apr; 27(4):1776-1782. PubMed ID: 27436021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy.
    Hosseiny M; Shakeri S; Felker ER; Lu D; Sayre J; Ahuja P; Raman SS
    AJR Am J Roentgenol; 2020 Sep; 215(3):660-666. PubMed ID: 32755166
    [No Abstract]   [Full Text] [Related]  

  • 15. Characterization of a novel liquid fiducial marker for multimodal image guidance in stereotactic body radiotherapy of prostate cancer.
    De Roover R; Crijns W; Poels K; Peeters R; Draulans C; Haustermans K; Depuydt T
    Med Phys; 2018 May; 45(5):2205-2217. PubMed ID: 29537613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance imaging-guided prostate biopsy: present and future.
    Kim CK
    Korean J Radiol; 2015; 16(1):90-8. PubMed ID: 25598677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
    Hoeks CM; Schouten MG; Bomers JG; Hoogendoorn SP; Hulsbergen-van de Kaa CA; Hambrock T; Vergunst H; Sedelaar JP; Fütterer JJ; Barentsz JO
    Eur Urol; 2012 Nov; 62(5):902-9. PubMed ID: 22325447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. End-to-end empirical validation of dose accumulation in MRI-guided adaptive radiotherapy for prostate cancer using an anthropomorphic deformable pelvis phantom.
    Bohoudi O; Lagerwaard FJ; Bruynzeel AME; Niebuhr NI; Johnen W; Senan S; Slotman BJ; Pfaffenberger A; Palacios MA
    Radiother Oncol; 2019 Dec; 141():200-207. PubMed ID: 31585817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer.
    Venderink W; van der Leest M; van Luijtelaar A; van de Ven WJM; Fütterer JJ; Sedelaar JPM; Huisman HJ
    World J Urol; 2017 Dec; 35(12):1849-1855. PubMed ID: 28871396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-clinical evaluation of an image-guided in-situ Raman spectroscopy navigation system for targeted prostate cancer interventions.
    Shams R; Picot F; Grajales D; Sheehy G; Dallaire F; Birlea M; Saad F; Trudel D; Menard C; Leblond F; Kadoury S
    Int J Comput Assist Radiol Surg; 2020 May; 15(5):867-876. PubMed ID: 32227280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.